Security
Biondvax Pharmaceuticals Ltd Ordinary Shares (Israel) · BVAXF
BVAXFOTCCommon stockHistorical · closed Feb 26, 2019CIK 1611747Updated Nov 18, 2026
BVAXF price & chart
This listing closed Feb 26, 2019. Live provider charts are shown only for current listings.
About the company
We are a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. We are advancing a pipeline of therapeutic candidates licensed from the Max Planck Society. We also own Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 25,093,000Source | 11,840,000Source | 14,851,000Source | 19,897,000Source | 24,449,000Source | 88,049,000Source | 23,292,000Source | — | 11,626,000Source | 13,448,000Source | 17,472,000Source | 27,067,000Source |
| Property, Plant and Equipment, NetUSD | — | 8,497,000Source | 10,180,000Source | 10,802,000Source | — | — | 10,817,000Source | — | 7,793,000Source | 9,189,000Source | 10,825,000Source | 11,245,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 989,000Source | 3,076,000Source | 7,506,000Source | 11,285,000Source | — | 10,799,000Source | 15,392,000Source | 1,661,000Source | 1,964,000Source | 4,870,000Source | 14,075,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 139,000Source | 119,000Source | — | — | — | — | — | 73,000Source | 83,000Source | — | — |
| Assets, CurrentUSD | — | 1,506,000Source | 3,657,000Source | 7,770,000Source | — | — | 11,045,000Source | — | 2,054,000Source | 2,391,000Source | 5,447,000Source | 14,370,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 236,000Source | 324,000Source | 138,000Source | — | — | — | — | 170,000Source | 213,000Source | 437,000Source | 45,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,837,000Source | 1,014,000Source | 1,325,000Source | — | — | 1,430,000Source | — | 1,779,000Source | 1,868,000Source | 1,200,000Source | 1,452,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 5,627,000Source | — | — | — | — | — | — | 5,627,000Source | 5,627,000Source | — | — |
| Additional Paid in CapitalUSD | — | 125,644,000Source | 121,272,000Source | 117,740,000Source | — | — | 116,431,000Source | — | 130,062,000Source | 123,629,000Source | 119,506,000Source | 116,082,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | -121,673,000Source | -126,816,000Source | -123,112,000Source | — | — | -119,350,000Source | — | -125,846,000Source | -117,539,000Source | -122,335,000Source | -115,835,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -1,740,000Source | -1,740,000Source | -1,740,000Source | — | — | -1,891,000Source | — | -1,740,000Source | -1,740,000Source | -1,740,000Source | -2,007,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | 7,858,000Source | -7,284,000Source | -7,112,000Source | 3,264,000Source | — | -4,810,000Source | -862,000Source | 8,103,000Source | 9,977,000Source | -4,569,000Source | -1,760,000Source |
| Liabilities and EquityUSD | — | 11,840,000Source | 14,851,000Source | 19,897,000Source | — | — | 23,292,000Source | — | 11,626,000Source | 13,448,000Source | 17,472,000Source | 27,067,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | 2,120,000Source | 1,672,000Source | 1,888,000Source | — | — | 2,579,000Source | — | 1,585,000Source | 1,806,000Source | 1,780,000Source | 2,338,000Source |
| Operating Lease, Liability, CurrentUSD | — | 497,000Source | 364,000Source | 394,000Source | — | — | — | — | 329,000Source | 424,000Source | 396,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | — | 1,566,000Source | 640,000Source | 927,000Source | — | — | 1,008,000Source | — | 1,644,000Source | 1,402,000Source | 797,000Source | 1,078,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | 441,000Source | 527,000Source | 461,000Source | 756,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | 90,000Source | 225,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 409,000Source | 284,000Source | 217,000Source | — |
| TradeAndOtherCurrentPayables | —Source | — | — | — | —Source | —Source | — | — | — | — | — | — |
| TradeAndOtherCurrentReceivables | —Source | — | — | — | —Source | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 138,000Source | 134,000Source | 1,421,000Source | 1,649,000Source | 514,000Source | 562,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 252,000Source | 485,000Source | 303,000Source | 682,000Source | 1,139,000Source | 1,602,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -10,000Source | 83,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,059,000Source | -1,105,000Source | -6,031,000Source | -6,335,000Source | -9,382,000Source | -7,265,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -6,000Source | -521,000Source | -24,000Source | -12,000Source | -637,000Source | -836,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 6,000Source | 521,000Source | 24,000Source | 12,000Source | 637,000Source | 836,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 5,770,000Source | 3,441,000Source | 1,086,000Source | 6,776,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,289,000Source | -1,985,000Source | -284,000Source | -2,915,000Source | -9,205,000Source | -3,302,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,131,000Source | 3,214,000Source | 7,632,000Source | 11,423,000Source | 10,926,000Source | 15,532,000Source | 1,811,000Source | 2,095,000Source | 5,010,000Source | 14,215,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 725,000Source | — | — | 143,000Source | 833,000Source | 916,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -224,000Source | -359,000Source | 1,000Source | -9,000Source | -272,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 252,000Source | 485,000Source | 304,000Source | 682,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 1,420,000Source | 1,648,000Source | — | 562,000Source |
| General and Administrative ExpenseUSD | — | 6,201,000Source | — | — | 1,141,000Source | 1,289,000Source | 1,191,000Source | 1,452,000Source | — | — | — | 1,502,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 8,130,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | -2,983,000Source | -3,515,000Source | -2,475,000Source | -8,307,000Source | 4,796,000Source | -6,500,000Source | -5,796,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | 6,415,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | -1,167,000Source | 280,000Source | -329,000Source | 140,000Source | -765,000Source | -1,325,000Source | — | 5,265,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | 4,890,000Source | 8,058,000Source | 9,706,000Source | — |
| Other Depreciation and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 514,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -359,000Source | -1,422,000Source | — | 5,100,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 5,265,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | — | — | — | — | — | — | 59,000Source | 59,000Source | 59,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 2,000,000Source | 139,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | 389Source | — | — |
| Profit or Loss | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
| AdjustmentsForSharebasedPayments | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2021 | Q3 2021 | Q2 2023 | Q2 2022 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | 1,311,000Source | 658,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — | — | — | —Source | —Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | 2,521,000Source | 2,526,000Source | 4,505,000Source | 5,296,000Source |
| Operating Income (Loss)USD | — | — | — | -3,263,000Source | -3,186,000Source | -2,615,000Source | -7,542,000Source | -8,638,000Source | 9,706,000Source | -11,061,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | -359,000Source | -1,422,000Source | — | 5,100,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -2,983,000Source | -3,515,000Source | -2,475,000Source | -8,307,000Source | 4,796,000Source | -6,500,000Source | -5,796,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0Source | -0Source | -0Source | -0Source | — | — | -0Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0Source | -0Source | -0Source | -0Source | — | — | -0Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,351,850,046Source | 746,898,671Source | 1,295,256,604Source | 744,711,465Source | 9,339,460,965Source | 3,225,472,266Source | 1,562,627,495Source | 754,076,407Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,351,850,046Source | 746,898,671Source | 1,295,256,604Source | 744,711,465Source | 9,339,460,965Source | 3,225,472,266Source | 1,562,627,495Source | 754,076,407Source |
| Additional Financial Items | ||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,421,000Source | 1,649,000Source | — | — |
| General and Administrative ExpenseUSD | — | 6,201,000Source | 1,141,000Source | 1,289,000Source | 1,191,000Source | 1,452,000Source | — | — | — | 1,502,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | -2,652,000Source | -580,000Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 8,130,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 343,000Source | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 2,968,000Source | — |
| Investment Income, NetUSD | — | — | — | — | — | — | 765,000Source | 1,325,000Source | 3,206,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | 6,415,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -1,167,000Source | 280,000Source | -329,000Source | 140,000Source | -765,000Source | -1,325,000Source | — | 5,265,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | 4,890,000Source | 8,058,000Source | 9,706,000Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | 788,000Source | 1,516,000Source | 941,000Source | — |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | 5,265,000Source |
| Research and Development ExpenseUSD | — | 2,024,000Source | — | 1,974,000Source | 1,995,000Source | 1,163,000Source | 2,369,000Source | 5,532,000Source | 5,210,000Source | 5,765,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 389Source | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | — | — | — | 8,307,000Source | -4,796,000Source | — | — |
| BasicEarningsLossPerShare | — | —Source | — | —Source | — | — | — | — | — | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | — | — | — | —Source | — | — | — | — | — | — |
| DilutedEarningsLossPerShare | — | —Source | — | —Source | — | — | — | — | — | — |
| FinanceCosts | — | —Source | — | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299674
Registration 333-299112
Registration 333-290437
Registration 333-295698
Filing attachments
ea031106001ex99-1.htm · 6-K · 2026-11-09
Exhibit 99.1 Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company operating a contract development and manufacturing organization (“CDMO”) alongside an immunology-focused therapeutic development platfo…
Read attachment ↗ea030984201ex4-5.htm · F-3 · 2026-10-28
Exhibit 4.5 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE INITIAL EXERCISE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) A.G.P./ALLIANCE GLOBAL PARTNERS OR ANOTHER PLACEMEN…
Read attachment ↗ea030914301ex99-1.htm · 6-K · 2026-10-20
Exhibit 99.1 Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and delivered JERUSALEM, Oct. 20, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) today issued the following letter to shareholders from Chief Executive Officer Amir Reichman. D…
Read attachment ↗ea030885201ex99-1.htm · 6-K · 2026-10-16
Exhibit 99.1 Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement JERUSALEM, October 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company operating a growing contract development and manufacturing organization (“CDMO”) alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placem…
Read attachment ↗ea030860501ex4-1.htm · 6-K · 2026-10-15
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ea030860501ex4-2.htm · 6-K · 2026-10-15
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗